This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cardiome Pharma Corp.
Drug Names(s): Kynapid, RSD1235, vernakalant hydrochloride (iv), MK-6621
Revenue splits are BioMedTracker estimates.
BioMedTracker has separate drug profiles for vernakalant hydrochloride. Please also see vernakalant hydrochloride (oral) for the oral formulation in development.
Vernakalant preferentially blocks the atrial specific (specific in the human but not rat heart) potassium channel Kv1.5 (Ikur), as well as other potassium channels (Ito and to a lesser extent, Ikr) and based on frequency, the sodium channel Ina.
Cardiome and Astellas
Cardiome Pharma Corp and Fujisawa Healthcare announced in October 2003 the execution of a US$68 million strategic partnership agreement, referred to as the North American Vernakalant (IV) Agreement, for the co-development and Fujisawa Healthcare's exclusive commercialization of Cardiome's vernakalant.
Under the terms of the agreement, Cardiome and Fujisawa Healthcare will co-develop vernakalant as an intravenous formulation for the treatment of atrial fibrillation and atrial flutter for North American markets. Cardiome receives an up-front payment of US$10 million upon execution of the agreement. In addition, Cardiome also has the right to place US$4 million of equity with Fujisawa at a premium to the 30-day average market price at any time over the next twelve months. Development and commercialization milestone payments totalling US$54 million will be payable to Cardiome on the achievement of specific development and commercial sales...See full deal structure in Biomedtracker
Partners: AOP Orphan Pharmaceuticals AG Biospifar SA Algorithm S.A.L. VIANEX SA Logista Pharma UDG Healthcare plc Aspen Pharmacare Holdings Limited Eddingpharm Chong Kun Dang Pharmaceutical Corp.
Additional information available to subscribers only: